17.71

1.23% 0.195

Novocure Ltd (NVCR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt NVCR? Forum Prognose

Schlusskurs vom Vortag:

$17.52

Offen:

$17.19

24-Stunden-Volumen:

210.13K

Relative Volume:

0.25

Marktkapitalisierung:

$1.90B

Einnahmen:

$577.74M

Nettoeinkommen (Verlust:

$-149.78M

KGV:

-12.65

EPS:

-1.4

Netto-Cashflow:

$-78.21M

1W Leistung:

-3.82%

1M Leistung:

-7.00%

6M Leistung:

+14.43%

1J Leistung:

+23.25%

1-Tages-Spanne:

$17.18

$17.88

1-Wochen-Bereich:

$17.18

$19.06

52-Wochen-Spanne:

$11.70

$34.13

Novocure Ltd Stock (NVCR) Company Profile

Firmenname

Novocure Ltd

Sektor

Healthcare (1165)

Branche

Medical Devices (161)

Telefon

44 (0)15 3475 6700

Adresse

NO. 4 THE FORUM, ST. HELIER

Mitarbeiter

1,453

Twitter

@novocure

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

NVCR's Discussions on Twitter

Vergleichen Sie NVCR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NVCR Novocure Ltd	17.74	1.90B	577.74M	-149.78M	-78.21M	-1.40
ABT Abbott Laboratories	131.69	225.32B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	100.75	149.74B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	374.75	142.48B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	88.62	113.49B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	72.08	42.10B	5.72B	4.17B	259.90M	6.97

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-02	Hochstufung	Evercore ISI	In-line → Outperform
2024-10-16	Hochstufung	H.C. Wainwright	Neutral → Buy
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-08-28	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-08-08	Hochstufung	Piper Sandler	Neutral → Overweight
2023-08-04	Eingeleitet	SVB Securities	Outperform
2023-07-31	Hochstufung	Evercore ISI	Underperform → In-line
2023-06-07	Hochstufung	Wedbush	Underperform → Neutral
2023-05-16	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-17	Herabstufung	JP Morgan	Neutral → Underweight
2023-01-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-01-05	Bestätigt	H.C. Wainwright	Buy
2022-11-29	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-10-24	Herabstufung	Piper Sandler	Overweight → Neutral
2022-07-05	Herabstufung	Evercore ISI	In-line → Underperform
2022-05-16	Eingeleitet	H.C. Wainwright	Buy
2022-02-08	Eingeleitet	Loop Capital	Buy
2022-02-02	Hochstufung	Oppenheimer	Perform → Outperform
2022-01-20	Hochstufung	Truist	Hold → Buy
2022-01-03	Hochstufung	Evercore ISI	Underperform → In-line
2021-07-01	Herabstufung	Mizuho	Buy → Neutral
2021-04-14	Herabstufung	Wedbush	Neutral → Underperform
2021-01-25	Bestätigt	Piper Sandler	Overweight
2020-09-23	Eingeleitet	Northland Capital	Outperform
2020-09-18	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-09-17	Herabstufung	Truist	Buy → Hold
2020-06-01	Fortgesetzt	Oppenheimer	Perform
2020-05-01	Herabstufung	Oppenheimer	Outperform → Perform
2020-04-09	Herabstufung	Evercore ISI	In-line → Underperform
2020-03-05	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-07-29	Hochstufung	SunTrust	Hold → Buy
2019-07-26	Herabstufung	JP Morgan	Overweight → Neutral
2019-07-26	Herabstufung	Wedbush	Outperform → Neutral
2019-03-20	Eingeleitet	SunTrust	Hold
2018-11-02	Herabstufung	Wells Fargo	Outperform → Market Perform
2018-07-16	Eingeleitet	Evercore ISI	Outperform
2018-04-18	Bestätigt	Mizuho	Buy
2018-02-23	Bestätigt	Mizuho	Buy
2017-05-24	Hochstufung	Wells Fargo	Market Perform → Outperform
2016-07-29	Bestätigt	Wedbush	Outperform
2016-01-19	Eingeleitet	Barclays	Underweight
2015-12-02	Eingeleitet	Deutsche Bank	Hold

Alle ansehen

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

Apr 01, 2025

Novocure to Report First Quarter 2025 Financial Results - Yahoo Finance

Apr 01, 2025

Mar 27, 2025

Emerald Advisers LLC Takes Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Mar 27, 2025

Mar 22, 2025

Proficio Capital Partners LLC Acquires Shares of 30,158 NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 22, 2025

Mar 21, 2025

NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Moderate Buy” from Analysts - The AM Reporter

Mar 21, 2025

Mar 19, 2025

NovoCure Beats Investor Lawsuit Over Cancer Trial Data Results - Bloomberg Law News

Mar 19, 2025

Charles Schwab Investment Management Inc. Has $24.92 Million Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 19, 2025

NovoCure Beats Investor Suit Over Cancer Therapy Trial Data (1) - Bloomberg Law News

Mar 19, 2025

NovoCure (NASDAQ:NVCR) Rating Increased to Hold at StockNews.com - Defense World

Mar 19, 2025

Mar 15, 2025

Bank of New York Mellon Corp Increases Stock Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 15, 2025

Mar 12, 2025

An Analysis of NovoCure Ltd (NVCR)’s Potential Price Growth - Knox Daily

Mar 12, 2025

Mar 11, 2025

Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields - Investing.com India

Mar 11, 2025

Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields By Investing.com - Investing.com UK

Mar 11, 2025

Mar 08, 2025

Principal Financial Group Inc. Invests $272,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 08, 2025

Mar 07, 2025

Novocure Ltd. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 06, 2025

Truist Financial Corp Invests $340,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 06, 2025

Don't Ignore The Insider Selling In NovoCure - Simply Wall St

Mar 06, 2025

Mar 05, 2025

Novocure’s EVP sells shares worth $46,841 By Investing.com - Investing.com Australia

Mar 05, 2025

Insider Sell Alert: Frank Leonard Sells 15,036 Shares of NovoCure Ltd (NVCR) - GuruFocus.com

Mar 05, 2025

Mar 04, 2025

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - MSN

Mar 04, 2025

Novocure’s chief innovation officer sells shares worth $5,071 - Investing.com India

Mar 04, 2025

Novocure’s EVP sells shares worth $46,841 - Investing.com India

Mar 04, 2025

Novocure CEO Ashley Cordova sells shares valued at $38,055 By Investing.com - Investing.com South Africa

Mar 04, 2025

Novocure CEO Ashley Cordova sells shares valued at $38,055 - Investing.com

Mar 04, 2025

Novocure COO sells shares worth $4,634 By Investing.com - Investing.com Australia

Mar 04, 2025

Novocure COO sells shares worth $4,634 - Investing.com

Mar 04, 2025

Novocure’s COO Paravasthu Mukund sells shares worth $39,687 By Investing.com - Investing.com Australia

Mar 04, 2025

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference - Yahoo Finance

Mar 04, 2025

NovoCure (NASDAQ:NVCR) Lowered to “Sell” Rating by StockNews.com - Defense World

Mar 04, 2025

Mar 03, 2025

Novocure executive sells shares for $296,256 By Investing.com - Investing.com South Africa

Mar 03, 2025

Novocure’s COO Paravasthu Mukund sells shares worth $39,687 - Investing.com India

Mar 03, 2025

Novocure CEO Ashley Cordova disposes shares worth $266,126 - Investing.com India

Mar 03, 2025

Novocure CEO Ashley Cordova disposes shares worth $266,126 By Investing.com - Investing.com Canada

Mar 03, 2025

Q1 Earnings Estimate for NovoCure Issued By Leerink Partnrs - Defense World

Mar 03, 2025

Mar 02, 2025

New York State Common Retirement Fund Increases Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 02, 2025

New York State Common Retirement Fund Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Armenian Reporter

Mar 02, 2025

Mar 01, 2025

Some Confidence Is Lacking In NovoCure Limited (NASDAQ:NVCR) As Shares Slide 25% - Simply Wall St

Mar 01, 2025

Los Angeles Capital Management LLC Acquires 55,334 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Mar 01, 2025

Rhumbline Advisers Buys 3,115 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 01, 2025

Feb 28, 2025

NovoCure (NASDAQ:NVCR) Posts Earnings Results, Misses Expectations By $0.27 EPS - MarketBeat

Feb 28, 2025

Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025

Commit To Buy NovoCure At $13, Earn 22.3% Using Options - Nasdaq

Feb 28, 2025

NovoCure (NASDAQ:NVCR) Shares Gap Down After Earnings Miss - MarketBeat

Feb 28, 2025

NovoCure Full Year 2024 Earnings: EPS Misses Expectations - Simply Wall St

Feb 28, 2025